Entity

Time filter

Source Type


Carrillo-Esper R.,Academia Nacional de Medicina
Medicina Interna de Mexico | Year: 2010

The measurement of intra-abdominal pressure is a new monitoring technique in critical ill patients. The intra-abdominal pressure can be related with intra-abdominal hypertension and abdominal compartmental syndrome the last has been associated with increased in morbidity and mortality. In the last few years, there has been progress in the understanding of the pathophysiology of abdominal compartmental syndrome leads to early diagnosis and appropriate and in the implementation of different treatment alternatives ranging from non-invasive approach to decompressive laparotomy. The aim of this paper is to describe the scientific evidence base to the current concepts related to the abdominal compartmental syndrome and intra-abdominal hypertension and its impact on clinical practice. Source


Raskob G.E.,The University of Oklahoma Health Sciences Center | Angchaisuksiri P.,Mahidol University | Blanco A.N.,Academia Nacional de Medicina | Gallus A.,Flinders Medical Center | And 8 more authors.
Journal of Thrombosis and Haemostasis | Year: 2014

Thrombosis is a common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2010 documented that ischemic heart disease and stroke collectively caused one in four deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. We performed a systematic review of the literature on the global disease burden caused by VTE in low-income, middle-income and high-income countries. Studies from western Europe, North America, Australia and southern Latin America (Argentina) yielded consistent results, with annual incidence rates ranging from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 per 1000 among those aged ≥ 70 years. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low, because of population aging. VTE associated with hospitalization was the leading cause of disability-adjusted life-years (DALYs) lost in low-income and middle-income countries, and the second most common cause in high-income countries, being responsible for more DALYs lost than nosocomial pneumonia, catheter-related bloodstream infections, and adverse drug events. VTE causes a major burden of disease across low-income, middle-income and high-income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems, and to evaluate whether improved utilization of preventive measures will reduce the burden. © 2014 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis. Source


Carrillo-Esper R.,Academia Nacional de Medicina | Medrano-del Angel T.,Fundacion Clinica Medica Sur
Revista Mexicana de Anestesiologia | Year: 2011

Delirium and Postoperative Cognitive Dysfunction (POCD) are well described complications both cardiac and non-cardiac surgery especially in the elderly. The estimated incidence is between 25-80% depending on the type of surgery, definition and the time of postoperative assessment. There seems to be a significant association between delirium and POCD and a decline in quality of life and higher mortality. This review describes the incidence, risk factors, definitions, patophysiology, diagnosis, treatment and long term consequences of delirium and POCD. Source


Raskob G.E.,The University of Oklahoma Health Sciences Center | Angchaisuksiri P.,Mahidol University | Blanco A.N.,Academia Nacional de Medicina | Gallus A.,Flinders Medical Center | And 8 more authors.
Arteriosclerosis, Thrombosis, and Vascular Biology | Year: 2014

Background-Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective.To review the literature on the global burden of disease caused by VTE.Approach and Results-We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 per 1000 among those aged .70 years. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low because of population aging. VTE associated with hospitalization was the leading cause of disability-adjusted life-years lost in low- and middle-income countries, and second in high-income countries, responsible for more disability-adjusted life-years lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events.Conclusions-VTE causes a major burden of disease across low-, middle-, and high-income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems and to evaluate whether improved use of preventive measures will reduce the burden. © 2014 American Heart Association, Inc. Source


Yaqub S.,Edwards Comprehensive Cancer Center | Ballester G.,Edwards Comprehensive Cancer Center | Ballester O.,Academia Nacional de Medicina
Cancer Investigation | Year: 2013

The past decade has seen significant progress in the development of new and effective therapies for multiple myeloma. Stem cell transplantation and the introduction of novel agents, such as thalidomide, lenalidomide, and bortezomib, have significantly improved outcomes of myeloma patients. In the current review, we analyzed the available data provided by published randomized clinical trials for the frontline therapy of myeloma patients. We attempted to assess the relative contribution and impact of these new therapies in the setting of both, transplant eligible and transplant ineligible patients. © 2013 Informa Healthcare USA, Inc. Source

Discover hidden collaborations